A major study has put two diabetes drugs head to head, and drawn some surprising conclusions. Avandia, a newer form of type 2 diabetes drug, was put alongside metformin and glyburide and thoroughly tested. Results indicated that Avandia provided better glucose control but posed a risk of greater side effects, not to mention a higher cost.
The study was conducted at the University of Washington . Glyburide was outperformed by both Avandia and Metformin, leading study author Steven Kahn to say: “People who use glyburide will have to think about changing drugs.”
The study was funded by the manufacturer of Avandia, GlaxoSmithKline, and investigated 4, 360 newly diagnosed diabetics . The flipside of the study, that proved the efficiency of Avandia, also revealed that 62 of the patients who took Avandia also developed a heart problem . When compared to the other drugs, 58 patients taking metformin and 41 taking glyburide developed similar heart problems .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…